| Project/Area Number |
23650192
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurochemistry/Neuropharmacology
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
TOOYAMA Ikuo 滋賀医科大学, 分子神経科学研究センター, 教授 (20207533)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 神経変性疾患 / 認知症 / アルツハイマー病 / 診断 / ベータアミロイド / 診断薬 / 体外診断 / 血液 |
|---|
| Research Abstract |
We have developed a novel curcumin derivative (Shiga-Y5), that can exist in an equilibrium between keto and enol tautomers, with the enol form able to bind Aβ aggregates while the keto form cannot. Using Shiga-Y5, we developed a hemodiagnostic method to detect Aβ deposition in the Tg2576 mouse, a model of AD. When Shiga-Y5 injected into tail veins of Tg2576 and wild mice, a delayed decreaserate of Shiga-Y5 clearance was observed in Tg2576 mice in comparison to wild-type mice. The delayed clearance of Shiga-Y5 from the brain into blood reflected amounts of Aβ depositions in the brain.
|
